← Leaderboards
Theresa L Chang
Mount Sinai School Of Medicine Of Nyu
$11,120,508
Attributed
$14,633,986
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,633,986 · 10
By mechanism
R01$12,340,885 · 4
R21$1,996,476 · 5
R56$296,625 · 1
Top collaborators
- Francois J Villinger5 shared
- Zhiheng Pei3 shared
- Liying Yang3 shared
- Yanxiang Guo1 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Valentin Fuster$27,161,393
- Vincent M Wang$2,016,615
- Ming-Ming Zhou$30,320,282
- Domenico Tortorella$11,580,055
- Steven J Kattman$150,772
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsInfectionWomanMediatingInsightMucous MembranePredispositionTransmission ProcessPlayVirusResponseImmune ResponseImmuneVaginaSexually Transmitted DiseasesViralBloodAids PreventionFemalePrevention StrategyImmunoregulationIn VitroCellsMolecular
Grant awards (34)
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir$766,944
R01 · FY2025 · DK · contact PI
Elucidate the role and mechanism of IFNε in Kras-driven lung tumorigenesis$220,193
R21 · FY2025 · CA
ACE2-independent alternative receptors for SARS-CoV-2 at the oral mucosa$196,250
R21 · FY2025 · DE · contact PI
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir$732,404
R01 · FY2024 · DK · contact PI
ACE2-independent alternative receptors for SARS-CoV-2 at the oral mucosa$235,500
R21 · FY2024 · DE · contact PI
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir$762,285
R01 · FY2023 · DK · contact PI
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir$761,967
R01 · FY2022 · DK · contact PI
Role of IFNe in immune modulation and HIV infection$602,815
R01 · FY2022 · AI · contact PI
Impact of gender affirming hormone therapy on immune modulation and HIV infection in transgender young adults$235,500
R21 · FY2022 · AI · contact PI
Sex difference in intestinal immune dysfunction, SHIV infection and reservoir$777,641
R01 · FY2021 · DK · contact PI
Role of IFNe in immune modulation and HIV infection$612,355
R01 · FY2021 · AI · contact PI
Impact of gender affirming hormone therapy on immune modulation and HIV infection in transgender young adults$195,834
R21 · FY2021 · AI · contact PI
Role of IFNe in immune modulation and HIV infection$683,760
R01 · FY2020 · AI · contact PI
Role of IFNe in immune modulation and HIV infection$804,864
R01 · FY2019 · AI · contact PI
Role of IFNe in immune modulation and HIV infection$719,947
R01 · FY2018 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$572,250
R01 · FY2017 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$606,004
R01 · FY2016 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$721,846
R01 · FY2015 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$21,091
R01 · FY2015 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$561,750
R01 · FY2014 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$455,292
R01 · FY2014 · AI · contact PI
Modulation of innate immunity,microbiome and HIV transmission by Depo-Provera$522,582
R01 · FY2013 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$351,988
R01 · FY2013 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$59,218
R01 · FY2013 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$35,165
R01 · FY2013 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$393,385
R01 · FY2012 · AI · contact PI
HIV-Human Peritonal Macrophage Interactions$197,700
R21 · FY2012 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$391,085
R01 · FY2011 · AI · contact PI
HIV-Human Peritonal Macrophage Interactions$253,400
R21 · FY2011 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$216,342
R01 · FY2010 · AI · contact PI
Defensins in STI-Mediated Enhanced HIV Infectivity$207,905
R01 · FY2010 · AI · contact PI
Defensins in STI-mediated enhancement of HIV Infection$207,849
R21 · FY2008 · AI · contact PI
Defensins in STI-mediated enhancement of HIV Infection$254,250
R21 · FY2007 · AI · contact PI
Mechanism of HIV-1 inhibition by alpha-defensin-1$296,625
R56 · FY2005 · AI